Tiomolibdate choline is under clinical development by Alexion Pharmaceuticals and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tiomolibdate choline’s likelihood of approval (LoA) and phase transition for Wilson Disease took place on 17 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tiomolibdate choline Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tiomolibdate choline overview
Tiomolibdate choline (WTX-101, ALXN-1840) is under development for the treatment of Wilson disease, amyotrophic lateral sclerosis (ALS) and primary biliary cholangitis. The drug candidate is a second-generation tetrathiomolybdate analog. It is formulated as a tablet and is administered through oral route. It acts by targeting SOD1. It was also under development for the treatment of advanced melanoma and multiple myeloma.
Alexion Pharmaceuticals overview
Alexion Pharmaceuticals (Alexion) discovers, develops, and markets therapies based on complement biology and inhibition for rare diseases. Deep understanding of rare disease enables the company to innovate and enter new areas, where there is a great unmet medical need. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. The company also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.
Quick View Tiomolibdate choline LOA Data
|Highest Development Stage|